Workflow
药明生物(02269)公布中期业绩 公司拥有人应占纯利约23.39亿元 同比增长56%
智通财经网·2025-08-19 11:12

Core Insights - WuXi Biologics (02269) reported a revenue of approximately 9.953 billion yuan for the first half of 2025, representing a year-on-year growth of 16.1% [1] - The gross profit was around 4.253 billion yuan, with a year-on-year increase of 27% [1] - The profit attributable to the company's owners was approximately 2.339 billion yuan, reflecting a significant year-on-year growth of 56% [1] - Adjusted profit attributable to the company's owners was about 2.389 billion yuan, showing a year-on-year increase of 6.2% [1] - Basic earnings per share stood at 0.58 yuan [1] Revenue Growth Drivers - Revenue growth was primarily driven by the successful execution of the "Winning Molecules" strategy, leading to enhanced project delivery times and execution records [1] - The expansion of service offerings in the biopharmaceutical industry, including research discovery, pre-IND development, and clinical and commercial production, was supported by rapidly developing technology platforms such as ADCs and bispecific antibodies [1] - Growth in research service revenue was attributed to multiple advanced technologies utilized by the company [1] - Increased utilization of existing and new production capacities, including ramp-up at European production facilities, contributed to revenue growth [1] Project and Order Metrics - The company achieved a record number of new integrated projects, adding 86 projects during the reporting period, bringing the total to 864 [2] - As of June 30, 2025, the number of preclinical and early clinical projects increased to 429 and 344, respectively, indicating sustainable development capabilities [2] - The late-stage clinical and commercial production projects also showed steady growth, with project counts reaching 67 and 24, respectively [2] - The company successfully secured 9 external projects during the reporting period, including 2 late-stage clinical projects, further enhancing growth momentum [2] - The total amount of uncompleted orders increased to 20.3 billion USD as of June 30, 2025, comprising 11.4 billion USD in uncompleted service orders and 9 billion USD in potential milestone payment orders [2] - The total uncompleted orders over the next three years reached 4.2 billion USD as of June 30, 2025, although the timing and probability of revenue recognition from potential milestone payments may vary due to factors beyond the company's control [2]